Striatal Dopamine Transporter Binding Does Not Correlate with Clinical Severity in Dementia with Lewy Bodies

Morten Ziebell; Birgitte B Andersen; Lars H Pinborg; Gitte M Knudsen; Jette Stokholm; Gerda Thomsen; Merete Karlsborg; Peter Høgh; Mette Louise Mørk; Steen G Hasselbalch

doi:10.2967/jnumed.112.114025

Striatal Dopamine Transporter Binding Does Not Correlate with Clinical Severity in Dementia with Lewy Bodies

Morten Ziebell, Birgitte B Andersen, Lars H Pinborg, Gitte M Knudsen, Jette Stokholm, Gerda Thomsen, Merete Karlsborg, Peter Høgh, Mette Louise Mørk, Steen G Hasselbalch

24 Citationer (Scopus)

Abstract

Patients who have dementia with Lewy bodies (DLB) show both clinical and histopathologic overlap with Alzheimer disease patients and Parkinson disease patients. In this study, we correlated the core features of DLB (dementia, parkinsonism, hallucinations, and fluctuations) with striatal dopamine transporter (DAT) availability as assessed with SPECT and ¹²³I-N-(3- iodoprop-2E-enyl)-2-β-carbomethoxy- 3b-(4-methylphenyl) nortropane (123I-PE2I) in patients with newly diagnosed DLB. Methods: Two hundred eighty-eight patients were consecutively included in the study as they were referred for diagnostic SPECT scanning of DAT with ¹²³I-PE2I. Of those patients, 51 had, on the basis of clinical guideline criteria, a probable- DLB diagnosis at follow-up 16 ± 11.6 mo later. Before or on the day of the SPECT scan, DLB patients had a routine neurologic examination including Hoehn and Yahr grading and were cognitively evaluated with the Mini Mental State Examination. Results: There was no correlation between Mini Mental State Examination, Hoehn and Yahr score, fluctuations or hallucinations, and striatal DAT availability as measured with ¹²³I-PE2I and SPECT. Conclusion: In patients with newly diagnosed DLB, symptoms are not associated with a reduction in striatal DAT despite its firm involvement in DLB pathology.

Originalsprog	Engelsk
Tidsskrift	Journal of Nuclear Medicine
ISSN	0161-5505
DOI	https://doi.org/10.2967/jnumed.112.114025
Status	Udgivet - 1 jul. 2013

Adgang til dokumentet

10.2967/jnumed.112.114025

Citationsformater

@article{64fc0c37581441b7a923dab5f933a94d,

title = "Striatal Dopamine Transporter Binding Does Not Correlate with Clinical Severity in Dementia with Lewy Bodies",

abstract = "Patients who have dementia with Lewy bodies (DLB) show both clinical and histopathologic overlap with Alzheimer disease patients and Parkinson disease patients. In this study, we correlated the core features of DLB (dementia, parkinsonism, hallucinations, and fluctuations) with striatal dopamine transporter (DAT) availability as assessed with SPECT and 123I-N-(3- iodoprop-2E-enyl)-2-β-carbomethoxy- 3b-(4-methylphenyl) nortropane (123I-PE2I) in patients with newly diagnosed DLB. Methods: Two hundred eighty-eight patients were consecutively included in the study as they were referred for diagnostic SPECT scanning of DAT with 123I-PE2I. Of those patients, 51 had, on the basis of clinical guideline criteria, a probable- DLB diagnosis at follow-up 16 ± 11.6 mo later. Before or on the day of the SPECT scan, DLB patients had a routine neurologic examination including Hoehn and Yahr grading and were cognitively evaluated with the Mini Mental State Examination. Results: There was no correlation between Mini Mental State Examination, Hoehn and Yahr score, fluctuations or hallucinations, and striatal DAT availability as measured with 123I-PE2I and SPECT. Conclusion: In patients with newly diagnosed DLB, symptoms are not associated with a reduction in striatal DAT despite its firm involvement in DLB pathology.",

author = "Morten Ziebell and Andersen, {Birgitte B} and Pinborg, {Lars H} and Knudsen, {Gitte M} and Jette Stokholm and Gerda Thomsen and Merete Karlsborg and Peter H{\o}gh and M{\o}rk, {Mette Louise} and Hasselbalch, {Steen G}",

year = "2013",

month = jul,

day = "1",

doi = "10.2967/jnumed.112.114025",

language = "English",

journal = "The Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine",

}

TY - JOUR

T1 - Striatal Dopamine Transporter Binding Does Not Correlate with Clinical Severity in Dementia with Lewy Bodies

AU - Ziebell, Morten

AU - Andersen, Birgitte B

AU - Pinborg, Lars H

AU - Knudsen, Gitte M

AU - Stokholm, Jette

AU - Thomsen, Gerda

AU - Karlsborg, Merete

AU - Høgh, Peter

AU - Mørk, Mette Louise

AU - Hasselbalch, Steen G

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Patients who have dementia with Lewy bodies (DLB) show both clinical and histopathologic overlap with Alzheimer disease patients and Parkinson disease patients. In this study, we correlated the core features of DLB (dementia, parkinsonism, hallucinations, and fluctuations) with striatal dopamine transporter (DAT) availability as assessed with SPECT and 123I-N-(3- iodoprop-2E-enyl)-2-β-carbomethoxy- 3b-(4-methylphenyl) nortropane (123I-PE2I) in patients with newly diagnosed DLB. Methods: Two hundred eighty-eight patients were consecutively included in the study as they were referred for diagnostic SPECT scanning of DAT with 123I-PE2I. Of those patients, 51 had, on the basis of clinical guideline criteria, a probable- DLB diagnosis at follow-up 16 ± 11.6 mo later. Before or on the day of the SPECT scan, DLB patients had a routine neurologic examination including Hoehn and Yahr grading and were cognitively evaluated with the Mini Mental State Examination. Results: There was no correlation between Mini Mental State Examination, Hoehn and Yahr score, fluctuations or hallucinations, and striatal DAT availability as measured with 123I-PE2I and SPECT. Conclusion: In patients with newly diagnosed DLB, symptoms are not associated with a reduction in striatal DAT despite its firm involvement in DLB pathology.

AB - Patients who have dementia with Lewy bodies (DLB) show both clinical and histopathologic overlap with Alzheimer disease patients and Parkinson disease patients. In this study, we correlated the core features of DLB (dementia, parkinsonism, hallucinations, and fluctuations) with striatal dopamine transporter (DAT) availability as assessed with SPECT and 123I-N-(3- iodoprop-2E-enyl)-2-β-carbomethoxy- 3b-(4-methylphenyl) nortropane (123I-PE2I) in patients with newly diagnosed DLB. Methods: Two hundred eighty-eight patients were consecutively included in the study as they were referred for diagnostic SPECT scanning of DAT with 123I-PE2I. Of those patients, 51 had, on the basis of clinical guideline criteria, a probable- DLB diagnosis at follow-up 16 ± 11.6 mo later. Before or on the day of the SPECT scan, DLB patients had a routine neurologic examination including Hoehn and Yahr grading and were cognitively evaluated with the Mini Mental State Examination. Results: There was no correlation between Mini Mental State Examination, Hoehn and Yahr score, fluctuations or hallucinations, and striatal DAT availability as measured with 123I-PE2I and SPECT. Conclusion: In patients with newly diagnosed DLB, symptoms are not associated with a reduction in striatal DAT despite its firm involvement in DLB pathology.

U2 - 10.2967/jnumed.112.114025

DO - 10.2967/jnumed.112.114025

M3 - Journal article

C2 - 23637201

SN - 0161-5505

JO - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

ER -

Striatal Dopamine Transporter Binding Does Not Correlate with Clinical Severity in Dementia with Lewy Bodies

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater